可成药基因组及其对药物开发中靶点识别与验证的支持
该研究将全基因组关联研究识别的复杂疾病及生物标志物相关位点与更新的可成药人类蛋白编码基因集、针对这些靶点的活性药物及已获批药物的临床适应症相连接,以描绘药物开发(包括重定位)机会,并利用该基因集指导新型基因分型芯片设计,以支持可成药基因的关联研究用于靶点选择与验证。
要点
- 将复杂疾病及生物标志物相关位点与可成药基因、活性药物及获批适应症连接。
- 该基因集用于指导设计新型基因分型芯片。
- 芯片将支持可成药基因关联研究用于靶点选择与验证。
核心结论
- 将复杂疾病及生物标志物相关位点与可成药基因、活性药物及获批适应症连接可描绘药物开发(包括重定位)机会。
研究设计与样本
- 研究将全基因组关联研究识别的复杂疾病及生物标志物相关位点与更新的可成药人类蛋白编码基因集、针对这些靶点的活性药物及已获批药物的临床适应症相连接。
主要发现
- 该基因集用于指导设计新型基因分型芯片,以支持可成药基因关联研究用于靶点选择与验证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in drug development. Clinically relevant associations of variants in genes encoding drug targets model the effect of modifying the same targets pharmacologically. To delineate drug development (including repurposing) opportunities arising from this paradigm, we connected complex disease- and biomarker-associated loci from genome-wide association studies to an updated set of genes encoding druggable human proteins, to agents with bioactivity against these targets, and, where there were licensed drugs, to clinical indications. We used this set of genes to inform the design of a new genotyping array, which will enable association studies of druggable genes for drug target selection and validation in human disease.
引用
- Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017. PMID: 28356508. doi:10.1126/scitranslmed.aag1166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。